The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 1, 2014, Pages 69-74

  Candido, Riccardo ^a  

^a ASS 1 Triestina   (Italy)

Author keywords

diabetic nephropathy; kidney; osteoprotegerin; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; GAMMA INTERFERON; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; VALSARTAN;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; KIDNEY; KIDNEY INJURY; KIDNEY TUBULE CELL; MACROALBUMINURIA; MICROALBUMINURIA; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION;

ANIMALS; APOPTOSIS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; OSTEOPROTEGERIN; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84890571567     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000437611.42417.7a     Document Type: Review

References (52)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-682.
2. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-12690.
3. Duiker EW, Mom CH, de Jong S, et al. The clinical trial of TRAIL. Eur J Cancer 2006; 42:2233-2240.
4. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004; 52:821-831.
5. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004; 113:58-64.
6. Krieg A, Krieg T, Wenzel M, et al. TRAIL-beta and TRAIL-gamma: Two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer 2003; 88:918-927.
7. Kamachi M, Aramaki T, Tanimura S, et al. Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosisinducing ligand (TRAIL): Potential effect on immune surveillance. Biochem Biophys Res Commun 2007; 360:280-285.
8. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281:1305-1308.
9. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-14367.
10. Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: A role in endothelial physiopathology Front Biosci 2008; 13:135-147.
11. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
12. Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells. Gene 1997; 204:35-46.
13. Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275:23319-23325.
14. Miyashita T, Kawakami A, Nakashima T, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 2004; 137:430-436.
15. Secchiero P, Candido R, Corallini F, et al. Systemic tumor necrosis factorrelated apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006; 114:1522-1530.
16. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006; 169:2236-2244.
17. Candido R, Toffoli B, Corallini F, et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res 2010; 47:252-261.
18. Toffoli B, Bernardi S, Candido R, et al. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012; 30:1257-1260. This is the first experimental study demonstrating that therapeutic administration of TRAIL might have a cardioprotective effect.
19. Bernardi S, Milani D, Fabris B, et al. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012; 13:1215-1221.
20. Toffoli B, Bernardi S, Candido R, et al. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011; 331:136-142.
21. Secchiero P, Perri P, Melloni E, et al. Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy. Diabet Med 2011; 28:1277-1278.
22. Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anticancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012; 7:207-217.
23. Wu XX, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004; 67:365-383.
24. Marini P. Drug evaluation: Lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor Curr Opin Mol Ther 2006; 8:539-546.
25. Norian LA, Kresowik TP, Rosevear HM, et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One 2012; 7:e31085. This review demonstrates eradication of metastatic renal cell carcinoma after adenovirus-encoded TRAIL/CpG immunotherapy in mice. A similar approach may prove beneficial for patients with metastatic renal cell carcinoma.
26. Takamizawa S, Okamoto S, Bishop W, et al. Differential apoptosis gene expression in pediatric tumors of the kidney. J Pediatr Surg 2000; 35:390-395.
27. Di Pietro R, Zauli G. Emerging nonapoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201:331-340.
28. Secchiero P, Zerbinati C, Rimondi E, et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004; 61:1965-1974.
29. Lorz C, Benito-Martin A, Boucherot A, et al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008; 19:904-914.
30. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-1361.
31. Sanchez-Nino MD, Sanz AB, Ihalmo P, Lassila M, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 2009; 20:353-362.
32. Chen B, Zhang Y, Liu G, Guan GJ, et al. Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats. [Chinese]. Zhonghua Yi Xue Za Zhi 2008; 88:540-545.
33. Chang YH, Lin KD, He SR, et al. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism 2011; 60:1064-1069.
34. Eichler T, Ma Q, Kelly C, et al. Single and combination toxic metal exposures induce apoptosis in cultured murine podocytes exclusively via the extrinsic caspase 8 pathway. Toxicol Sci 2006; 90:392-399.
35. Nguyen V, Cudrici C, Zernetkina V, et al. TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. Clin Immunol 2009; 132:32-42.
36. Okuyama S, Komatsuda A, Wakui H, et al. Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome. Nephrol Dial Transplant 2005; 20: 539-544.
37. Song CJ, Liu XS, Zhu Y, et al. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation. Transplant Proc 2004; 36:1340-1343.
38. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
39. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42:303-309.
40. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002; 40:1019-1023.
41. Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39:525-532.
42. Rasmussen LM, Tarnow L, Hansen TK, et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154:75-81.
43. Doi S, Yorioka N, Masaki T, et al. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. Ther Apher Dial 2004; 8:335-339.
44. Upadhyay A, Larson MG, Guo CY, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011; 26:920-926.
45. Jorsal A, Tarnow L, Flyvbjerg A, et al. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia2008; 51:2100-2107
46. Gordin D, Soro-Paavonen A, Thomas MC, et al. Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. Diabetes Care 2013; 36:1827-1833. This article shows that OPG concentrations are elevated only in type 1 diabetes patients with macroalbuminuria and/or renal impairment and that in these populations serum OPG is an independent predictor of cardiovascular complications
47. Wang ST, Xu JM, Wang M, et al. Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria. Clin Nephrol 2013; 79:192-198. This article demonstrates that plasma values of OPG are elevated in type 1 diabetes patients with nephropathy and gradually increased with the severity, so there is an association between plasma OPG levels and the presence and severity of diabetic nephropathy. This finding supports the growing concept that OPG may act as an important regulatory molecule in angiopathy and, particularly, that it may be involved in the development of nephropathy in type 1 diabetes.
48. Anand DV, Lahiri A, Lim E, et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47:1850-1857.
49. Benito-Martin A, Ucero AC, Santamaria B, et al. Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy [Spanish]. Nefrologia 2009; 29:13-19.
50. El-Shehaby A, Darweesh H, El-Khatib M, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011; 31:848-856.
51. Scialla JJ, Leonard MB, Townsend RR, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2612-2619.
52. Svensson M, Dahle DO, Mjoen G, et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: Follow-up data from the ALERT study. Nephrol Dial Transplant 2012; 27:2571-2575.